Patients at the center of our collective effort

Patients at the center of our collective effort

In our work at The Max Foundation, we treat every person facing cancer not just as a patient, but as an individual who belongs to a family and a community. Access to treatment is one of many barriers that patients face throughout their cancer journey.

We asked our partner hematologist in Malaysia, Dr. Ong Tee Chuan, to share his experience helping patients navigate their cancer journey and shed light on the various implications of treatment access. Dr. Ong has been practicing hematology for over 20 years, and is a clinician at Hospital Ampang in Selangor.

Dr Ong Tee Chuan (most right) with his fellow haematologist colleagues.
How do you explain access to treatment?

Dr. Ong: Access to cancer treatment— and to any medical intervention as a whole, be it health care, diagnostic testing, or treatment modalities—has significant clinical impact in patients’ outcome.

Once a treatment strategy has been proven to have high clinical value, it is important to ensure the universal availability of the treatment to all patients who need it. Universal availability does not mean free for everyone, but [[treatment]] should be available according to a cost that is affordable to the needed population.

In this case, much is relied on the healthcare financing and delivery system of each community, which is obviously an extremely complicated issue.

Based on your experience treating many patients, what are some of the barriers that patients and families face with access to treatment?

Dr. Ong: Access to treatment starts from access to health care, which in the ideal world must be simple, hassle-free, close to home, and affordable. The most obvious hurdle is the cost.

However, in the real world, even if the needed medication can be supplied at an affordable cost (or even free), there are still many logistical issues to look at. Constraints on the patient’s socio-economic condition can hinder access to treatment.

We have to realize that healthcare delivery is extremely complicated and intertwined with every aspect: politics and policy, economy, societal values and beliefs … just to name a few. Treating a disease might be a biomedical model, but managing a patient must go beyond biomedical thinking.

In 2014, you initiated a project helping children of cancer patients continue schooling while their parents were undergoing treatment. Can you tell us about The Max Schooling Project (Projek Sambung Sekolah) and how this project developed?

Dr. Ong: There are many hidden reasons why some patients cannot follow a treatment plan. For highly curable cancers, compliance to a treatment plan is one of the most important factors to cure the disease and to restore health.

Many patients earn daily or weekly wages, and many don’t have an adequate safety net for getting full wages while on prolonged medical leave from work. We have seen families struggle economically when the bread winner must stop working due to illness and the demanding schedule for treatment.

Children of patients are the unseen victims of disease; some might stop going to school for economic reasons or social reasons (no one can send them to and pick them up from school).

We believe that patients should not suffer from social-economic hardships when they have a catastrophic illness. The Max Schooling Project aims to give assistance to the children of patients, to help maximize their chance to complete at least secondary education.

Have you seen a change in treatment outcome for parents with children part of The Max Schooling Project?

Dr. Ong: The main aim of The Max Schooling Project is trying to ensure the affected child can have a life like their other peers.

They can join an outing organized by the school (when fees are needed), the family can have a meal in a restaurant when a milestone of treatment is achieved, or the kids can buy some extra materials during school activities.

Treating a disease must not be the top priority, it is how we treat each patient as an individual, a unique individual. Many kids benefit from the support, and we believe there is significant and sustained ripple effects from preventing [cancer patients’] children from dropping out from schools.

What does access to treatment mean to you?

Dr. Ong recently published a book, Tales of Medicine and Mankind, about health care policy, treatment access, and delivery. Part of the book sales are going toward The Max Schooling Project. Read The Max Schooling Project 2020 Report to learn more.

Mei Ching Ong is the Region Head of Asia Pacific, Eastern Europe and Central Asia. Mei Ching is based in our regional office located in Kuala Lumpur, Malaysia. Although growing up in a town facing the South China Sea with beautiful beaches, she is enjoying mountains, jungles and greens more than water, that explains she is spending most of her early morning during weekends in greens. Believing in everyone is connected with each another in this cycle we call life, Mei Ching also believes everyone has roles to play to strengthen the overall well-being of lives of human.

Related Articles

  • Road to Laos: Joy as first MAS Shipment of Medication Arrives!

    Road to Laos: Joy as first MAS Shipment of Medication Arrives!

    After weeks of anxious anticipation, February 10, 2023, was a day of incredible joy for us as the first shipment of medication successfully arrived in our partner hospital in Laos and soon into the welcoming hands of the patients – specifically young Ammonlath! Journey kicks off! Our journey started a year ago, in Jan 2022,….

  • The Max Schooling Project: Empowering Patients and Families through Continuing Education

    The Max Schooling Project: Empowering Patients and Families through Continuing Education

    Launched in 2014, The Max Schooling Project (“Projek Sambung Sekolah” in Malay) enables the children of cancer patients to continue their educations and graduate from Form Five – the equivalent of high school in Malaysia.

  • Partnering to Bring Access to PCR and Mutation Testing to the Philippines

    Partnering to Bring Access to PCR and Mutation Testing to the Philippines

    For people living with chronic myeloid leukemia (CML), regular disease monitoring using polymerase chain reaction (PCR) testing is critical to achieving successful health outcomes. Mutation testing is another key test for individuals who fail to respond to one or more treatments. Despite the importance of these tests, they are unaffordable and therefore inaccessible for many people living with CML in the Philippines.